Bayer Spins Off Respiratory Products To Aerovance
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Bayer execs are forming the biotech firm with funding from Apex Partners. Aerovance's lead products are an IL4/13 receptor antagonist for severe asthma entering Phase II, and a recombinant therapeutic protein for chronic obstructive pulmonary disease and cystic fibrosis planned for Phase I.